Gilead Sciences Inc.
Gilead Sciences Reports Q3 2025 Financial Results and Business Updates
Summary
Gilead Sciences, Inc. reported its third quarter 2025 financial results, showing a total revenue of $7.8 billion, a 3% increase year-over-year. Product sales excluding Veklury increased by 4% to $7.1 billion, driven by higher sales of HIV and liver disease products. Diluted earnings per share (EPS) were $2.43, significantly higher than the $1.00 reported in Q3 2024. Gilead also provided an update on its product pipeline and recent patent settlement agreements for Biktarvy.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement